Q1 Earnings Forecast for TARS Issued By Lifesci Capital

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Equities research analysts at Lifesci Capital issued their Q1 2025 earnings per share estimates for Tarsus Pharmaceuticals in a research note issued to investors on Wednesday, February 26th. Lifesci Capital analyst C. Jubinville forecasts that the company will post earnings of ($0.78) per share for the quarter. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals’ Q1 2025 earnings at ($0.78) EPS, Q2 2025 earnings at ($0.48) EPS and Q3 2025 earnings at ($0.31) EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The firm had revenue of $66.41 million for the quarter, compared to analysts’ expectations of $58.80 million.

Several other research firms have also weighed in on TARS. Barclays dropped their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday. HC Wainwright restated a “buy” rating and set a $73.00 price target on shares of Tarsus Pharmaceuticals in a research report on Wednesday. The Goldman Sachs Group lifted their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, November 15th. Oppenheimer lifted their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. Finally, Guggenheim reissued a “buy” rating and issued a $78.00 target price (up from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $61.33.

Tarsus Pharmaceuticals Trading Up 2.1 %

NASDAQ TARS opened at $44.48 on Friday. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals has a twelve month low of $20.08 and a twelve month high of $57.28. The firm has a market capitalization of $1.70 billion, a PE ratio of -11.67 and a beta of 1.01. The stock’s 50 day moving average is $50.97 and its 200 day moving average is $43.13.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of TARS. Creative Planning bought a new position in shares of Tarsus Pharmaceuticals during the third quarter valued at $362,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Tarsus Pharmaceuticals by 64.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,317 shares of the company’s stock valued at $241,000 after purchasing an additional 2,879 shares in the last quarter. Emerald Mutual Fund Advisers Trust bought a new position in shares of Tarsus Pharmaceuticals during the third quarter valued at $3,608,000. Harbor Capital Advisors Inc. lifted its holdings in shares of Tarsus Pharmaceuticals by 57.5% during the third quarter. Harbor Capital Advisors Inc. now owns 18,105 shares of the company’s stock valued at $595,000 after purchasing an additional 6,612 shares in the last quarter. Finally, Emerald Advisers LLC purchased a new stake in Tarsus Pharmaceuticals during the third quarter valued at $4,812,000. 90.01% of the stock is owned by institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.